BI 1026706
Sponsors
Boehringer Ingelheim
Conditions
HealthyMacular EdemaOsteoarthritisPain, PostoperativePulmonary Disease, Chronic Obstructive
Phase 1
To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706
CompletedNCT01763333
Start: 2013-01-08End: 2013-09-04Updated: 2019-03-25
Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers
CompletedNCT02037165
Start: 2014-01-21End: 2014-04-15Updated: 2019-07-05
Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain
CompletedNCT02084511
Start: 2014-03-31End: 2014-10-31Updated: 2019-04-12
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee
CompletedNCT02126826
Start: 2014-05-28End: 2014-10-21Updated: 2019-03-25
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects
CompletedNCT02513446
Start: 2015-09-29End: 2015-11-20Updated: 2019-03-29
Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
CompletedNCT02642614
Start: 2016-01-25End: 2016-06-14Updated: 2019-08-05
Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers
CompletedNCT02652416
Start: 2016-09-16End: 2016-12-09Updated: 2019-07-11
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
CompletedNCT02657408
Start: 2016-03-11End: 2017-03-13Updated: 2019-07-10